### Analysis of rs1057519999 and Its Clinical Phenotype Influence

The variant **rs1057519999** is located on **chromosome 17 at position 7674247** within the **TP53 gene**, a well-known tumor suppressor gene. This gene plays a critical role in regulating cell cycle, DNA repair, and apoptosis. Variants in TP53 are often associated with cancer predisposition syndromes and various malignancies.

---

### 1. **Variant Identification**
- **rs Number**: [rs1057519999](https://identifiers.org/dbsnp/rs1057519999)
- **Gene**: TP53
- **HGVS Notations**:
  - Genomic: `chr17:g.7674247T>A`, `chr17:g.7674247T>C`, `chr17:g.7674247T>G`
  - Protein (most common transcript): 
    - `p.Asn239Ile` (T>A)
    - `p.Asn239Ser` (T>C)
    - `p.Asn239Thr` (T>G)
- **Transcript**: Multiple transcripts are affected, including canonical transcript **NM_000546.6**.

---

### 2. **Disease Associations**
The clinical significance of rs1057519999 varies depending on the specific nucleotide change (T>A, T>C, or T>G). Below are the key findings:

#### a. **T>A (p.Asn239Ile)**
- **Associated Diseases**:
  - **Li-Fraumeni Syndrome** (ClinVar: [VCV002748594](https://www.ncbi.nlm.nih.gov/clinvar/variation/2748594))
  - **Small Cell Lung Carcinoma**
  - **Pleuropulmonary Blastoma**
- **Clinical Significance**: Uncertain significance (US) in ClinVar.
- **Predictive Models**:
  - **SIFT**: 0.0 (deleterious)
  - **PolyPhen**: 1.0 (probably damaging)
  - **AlphaMissense**: 0.9897 (likely pathogenic)

#### b. **T>C (p.Asn239Ser)**
- **Associated Diseases**:
  - **Hereditary Cancer-Predisposing Syndrome** (ClinVar: [VCV000376637](https://www.ncbi.nlm.nih.gov/clinvar/variation/376637))
  - **Li-Fraumeni Syndrome**
  - **Breast Neoplasm**
  - **Lung Adenocarcinoma**
- **Clinical Significance**: Likely pathogenic (LP) in ClinVar.
- **Predictive Models**:
  - **SIFT**: 0.02 (deleterious)
  - **PolyPhen**: 0.999 (probably damaging)
  - **AlphaMissense**: 0.7939 (likely pathogenic)

#### c. **T>G (p.Asn239Thr)**
- **Associated Diseases**:
  - **Hereditary Cancer-Predisposing Syndrome** (ClinVar: [VCV000376638](https://www.ncbi.nlm.nih.gov/clinvar/variation/376638))
  - **Li-Fraumeni Syndrome**
  - **Prostate Adenocarcinoma**
  - **Gastric Adenocarcinoma**
- **Clinical Significance**: Likely pathogenic (LP) or pathogenic (P) in ClinVar.
- **Predictive Models**:
  - **SIFT**: 0.0 (deleterious)
  - **PolyPhen**: 0.999 (probably damaging)
  - **AlphaMissense**: 0.9759 (likely pathogenic)

---

### 3. **Literature Evidence**
- Variants in TP53, particularly at codon 239, have been implicated in **Li-Fraumeni Syndrome**, a hereditary cancer predisposition syndrome. This syndrome is characterized by early-onset cancers, including sarcomas, breast cancer, brain tumors, and adrenocortical carcinoma.
- The specific amino acid changes (Asn239Ile, Asn239Ser, Asn239Thr) may alter the DNA-binding domain of the TP53 protein, impairing its tumor suppressor function.

---

### 4. **Allele Frequency Comparison**
- **Global Frequency**:
  - T>C: 6.84 × 10⁻⁷ (gnomAD exomes)
  - T>G: 6.84 × 10⁻⁷ (gnomAD exomes), 6.58 × 10⁻⁶ (gnomAD genomes)
- **Japanese Population**: No specific allele frequency data for Japanese populations is available in the retrieved dataset.

---

### 5. **GWAS Findings**
No specific genome-wide association studies (GWAS) findings were retrieved for rs1057519999. However, TP53 variants are frequently implicated in cancer-related GWAS.

---

### 6. **TogoVar Link**
- [TogoVar rs1057519999](https://togovar.org/variant/rs1057519999)

---

### Summary
The location of rs1057519999 in the TP53 gene significantly influences the clinical phenotype, particularly in cancer predisposition syndromes like **Li-Fraumeni Syndrome**. The specific nucleotide change determines the severity and type of associated diseases, with predictive models consistently indicating a deleterious effect on protein function.

---

### 日本語での説明

#### 1. **バリアントの特定**
- **rs番号**: [rs1057519999](https://identifiers.org/dbsnp/rs1057519999)
- **遺伝子**: TP53
- **HGVS表記**:
  - ゲノム: `chr17:g.7674247T>A`, `chr17:g.7674247T>C`, `chr17:g.7674247T>G`
  - タンパク質: 
    - `p.Asn239Ile` (T>A)
    - `p.Asn239Ser` (T>C)
    - `p.Asn239Thr` (T>G)
- **トランスクリプト**: 複数のトランスクリプトが影響を受ける（例: **NM_000546.6**）。

---

#### 2. **疾患との関連**
rs1057519999の臨床的意義は、特定の塩基変化（T>A, T>C, T>G）によって異なります。

##### a. **T>A (p.Asn239Ile)**
- **関連疾患**:
  - **リ・フラウメニ症候群**
  - **小細胞肺癌**
  - **胸膜肺芽腫**
- **臨床的意義**: 不明（US）
- **予測モデル**:
  - **SIFT**: 0.0（有害）
  - **PolyPhen**: 1.0（おそらく有害）
  - **AlphaMissense**: 0.9897（病原性の可能性が高い）

##### b. **T>C (p.Asn239Ser)**
- **関連疾患**:
  - **遺伝性がん素因症候群**
  - **リ・フラウメニ症候群**
  - **乳がん**
  - **肺腺がん**
- **臨床的意義**: おそらく病原性（LP）
- **予測モデル**:
  - **SIFT**: 0.02（有害）
  - **PolyPhen**: 0.999（おそらく有害）
  - **AlphaMissense**: 0.7939（病原性の可能性が高い）

##### c. **T>G (p.Asn239Thr)**
- **関連疾患**:
  - **遺伝性がん素因症候群**
  - **リ・フラウメニ症候群**
  - **前立腺腺がん**
  - **胃腺がん**
- **臨床的意義**: おそらく病原性（LP）または病原性（P）
- **予測モデル**:
  - **SIFT**: 0.0（有害）
  - **PolyPhen**: 0.999（おそらく有害）
  - **AlphaMissense**: 0.9759（病原性の可能性が高い）

---

#### 3. **文献的証拠**
TP53の239番目のコドンにおける変異は、**リ・フラウメニ症候群**に関連しており、この症候群は肉腫、乳がん、脳腫瘍、副腎皮質がんなどの早期発症が特徴です。

---

#### 4. **アレル頻度の比較**
- **全世界頻度**:
  - T>C: 6.84 × 10⁻⁷ (gnomAD exomes)
  - T>G: 6.84 × 10⁻⁷ (gnomAD exomes), 6.58 × 10⁻⁶ (gnomAD genomes)
- **日本人集団**: 日本人集団における頻度データは取得されていません。

---

#### 5. **GWASの発見**
rs1057519999に関連する特定のGWASの発見はありませんが、TP53変異はがん関連のGWASで頻繁に報告されています。

---

#### 6. **TogoVarリンク**
- [TogoVar rs1057519999](https://togovar.org/variant/rs1057519999)

---

### まとめ
rs1057519999はTP53遺伝子内に位置し、特定の塩基変化により、**リ・フラウメニ症候群**やその他のがん素因症候群に関連します。この変異は、TP53タンパク質のDNA結合ドメインに影響を与え、腫瘍抑制機能を損なう可能性があります。